To appraise the clinical and cost effectiveness of cabozantinib within its marketing authorisation for untreated locally advanced or metastatic renal cell carcinoma.
Status In progress
Process STA pre-2018
ID number 1208

Provisional Schedule

Expected publication 03 October 2018

Project Team

Project lead Jeremy Powell

Email enquiries


Companies sponsors Ipsen (cabozantinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Kidney Cancer Support Network
  Kidney Cancer UK
Professional groups Association of Cancer Physicians
  British Uro-Oncology Group
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists


Associated public health groups Public Health England
  Public Health Wales
Comparator companies EUSA Pharma (tivozanib) – not paticipating
  Novartis Pharmaceuticals (pazopanib)
  Pfizer (sunitinib)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute


Key events during the development of the guidance:

Date Update
05 June 2018 - 26 June 2018 Appraisal consultation
10 May 2018 Committee meeting: 1
05 December 2017 Invitation to participate
05 December 2017 In progress, Appraisal has begun
29 August 2017 - 26 September 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance